US and Brazil clear path for Pfizer’s Hospira buyout

26-08-2015

Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.


Pfizer, Hospira, anti-competition, Federal Trade Commission, drugs, pharma

LSIPR